Published • loading... • Updated
US FDA approves updated COVID vaccines for 2026-27 season
The updated shots target the XFG subvariant and are approved for older adults and younger people with high-risk conditions.
- On Thursday, the U.S. Food and Drug Administration approved Moderna's updated Spikevax and mNEXSPIKE vaccines for the 2026-27 season, targeting the JN.1-lineage XFG subvariant of SARS-CoV-2.
- Following an expert panel's May recommendation to prioritize the XFG variant, regulators also authorized updated COVID-19 vaccines from Pfizer-BioNTech and Novavax-Sanofi on the same day.
- Moderna Chief Executive Officer Stéphane Bancel noted that COVID-19 caused up to 2.3 million outpatient visits last year. Updated Spikevax is approved for ages 6 months through 64 years with underlying conditions and all adults 65 and older.
- Myocarditis and pericarditis have occurred most commonly in males 12 years through 24 years of age following mRNA vaccination. Recipients should seek immediate medical attention for chest pain or shortness of breath within 2 weeks of vaccination.
- Beyond the United States, the Spikevax formula has already received regulatory approval in Europe, the United Kingdom, Switzerland, Singapore, and South Korea, with additional applications under review globally.
Insights by Ground AI
25 Articles
25 Articles
Fall COVID Vaccines Receive FDA Approval
New COVID shots got the green light on Thursday, but actually getting one might not be straightforward. The FDA authorized updated vaccines from Moderna, Pfizer, and Sanofi/Novavax for this fall, aimed at the XFG variant now dominant in North America, the New York Times reports. Eligibility mirrors last year's: everyone...
·Miami, United States
Read Full Article
FDA approves new COVID-19 shots
The Food and Drug Administration approved updated COVID-19 vaccines on Thursday for people at higher risk, clearing the way for manufacturers to begin shipping them to pharmacies and physicians’ offices. The agency greenlit new formulations of the mRNA vaccines from Pfizer-BioNTech and Moderna, the companies said. FDA also approved a non-mRNA shot from Sanofi, which…
·Washington, United States
Read Full Article
Coverage Details
Total News Sources25
Leaning Left3Leaning Right2Center18Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
13%
C 78%
Factuality
To view factuality data please Upgrade to Premium
